SCHEMBL21755693

SCHEMBL21755693

CCCC(O)CCCCc1ccc(C)c(OC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.59
LTA4H P09960 5/20 0.49
CYP3A4 P08684 4/20 0.49
CYP2C8 P10632 3/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2B6 P20813 3/20 0.49
CYP2C19 P33261 3/20 0.49
TRPV1 Q8NER1 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 2/20 0.48
CYP2A6 P11509 2/20 0.48
CYP2E1 P05181 1/20 0.48
STAT3 P40763 1/20 0.48
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
ADRB2 P07550 2/20 0.43
TUBB4A P04350 1/20 0.43
TUBB P07437 1/20 0.43
TUBA3C P0DPH7 1/20 0.43
TUBA1B P68363 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23428645 0.99 HTR1A (0.61) HTR1ALTA4HCYP3A4CYP2C8CYP2C9
SCHEMBL14747877 0.96 HTR1A (0.56) HTR1ALTA4HCYP3A4CYP2C8CYP2C9
SCHEMBL19389985 0.82 HTR1A (0.47) HTR1ALTA4HCYP3A4CYP2C8CYP2C9
SCHEMBL15760679 0.82 TUBB4A (0.53) CYP3A4CYP1A2CYP2D6PPARGPPARA
SCHEMBL23370746 0.81 HTR1A (0.87) HTR1ALTA4HCYP3A4CYP2C8CYP2C9
SCHEMBL12020315 0.80 SKP2 (0.53) HTR1ACYP3A4CYP2C8CYP2C9CYP2B6
SCHEMBL17637575 0.80 TUBB4A (0.51) CYP3A4CYP1A2CYP2D6PPARGPPARA
SCHEMBL5702631 0.80 HTR1A (0.90) HTR1ALTA4HCYP3A4CYP2C8CYP2C9
SCHEMBL14747866 0.79 TUBB4A (0.43) HTR1ACYP3A4TRPV1STAT3PPARG
SCHEMBL14747869 0.79 HTR1A (0.41) HTR1ALTA4HCYP3A4CYP2C8CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10570154-B2 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10570154-B2 Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders BRSK2, STK3, BRSK1 HTR1A 2218/4885LTA4H 4260/4885CYP3A4 3981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.